Rachel E Sanborn Selected Research

Rachel E Sanborn Research Topics

Disease

22	Neoplasms (Cancer) 02/2024 - 08/2005
17	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 11/2023 - 11/2008
3	Disease Progression 11/2023 - 01/2015
3	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2022 - 01/2017
2	Fatigue 02/2024 - 10/2017
2	Diarrhea 02/2024 - 11/2021
2	Dyspnea (Shortness of Breath) 01/2023 - 01/2021
2	Nausea 01/2023 - 12/2008
2	Vomiting 01/2023 - 12/2008
2	Thrombocytopenia (Thrombopenia) 01/2022 - 10/2017
2	Colitis 01/2021 - 03/2016
2	Lung Neoplasms (Lung Cancer) 11/2019 - 10/2017
1	Thymoma (Thymic Carcinoma) 02/2024
1	Chills 01/2023
1	Flushing 01/2023
1	Melanoma (Melanoma, Malignant) 01/2023
1	Neutropenia 01/2022
1	Anemia 01/2022
1	Breast Neoplasms (Breast Cancer) 01/2022
1	Pneumonia (Pneumonitis) 01/2021
1	Colorectal Neoplasms (Colorectal Cancer) 12/2018
1	Inflammation (Inflammations) 01/2018
1	Lymphopenia (Lymphocytopenia) 12/2017
1	Pleural Effusion (Pleural Effusions) 12/2017
1	Fever (Fevers) 10/2017
1	Urinary Bladder Neoplasms (Bladder Cancer) 10/2016
1	Myasthenia Gravis 03/2016
1	Pericardial Effusion 03/2016

Drug/Important Bio-Agent (IBA)

6	Immune Checkpoint InhibitorsIBA 02/2024 - 04/2014
6	PlatinumIBA 11/2023 - 12/2008
5	Tyrosine Kinase InhibitorsIBA 02/2024 - 01/2009
5	ErbB Receptors (EGF Receptor)IBA 11/2023 - 01/2009
4	amivantamab-vmjwIBA 11/2023 - 10/2021
3	NivolumabIBA 02/2024 - 01/2022
3	AntigensIBA 01/2023 - 04/2014
3	Irinotecan (Camptosar)FDA LinkGeneric 01/2020 - 10/2017
3	Pemetrexed (MTA)FDA Link 01/2018 - 07/2013
3	Monoclonal AntibodiesIBA 10/2016 - 03/2006
2	Aspartate Aminotransferases (Aspartate Transaminase)IBA 02/2024 - 01/2021
2	Programmed Cell Death 1 ReceptorIBA 02/2024 - 01/2021
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 02/2024 - 03/2006
2	Immunoconjugates (Immunoconjugate)IBA 01/2022 - 01/2021
2	Lipase (Acid Lipase)FDA Link 11/2021 - 03/2016
2	Peptide Hydrolases (Proteases)FDA Link 01/2021 - 01/2021
2	carfilzomibIBA 01/2020 - 10/2017
2	Cisplatin (Platino)FDA LinkGeneric 01/2018 - 12/2008
2	Docetaxel (Taxotere)FDA Link 12/2017 - 01/2015
2	durvalumabIBA 10/2016 - 03/2016
2	Erlotinib Hydrochloride (CP 358,774)FDA Link 10/2012 - 01/2009
1	vorolanibIBA 02/2024
1	Platelet-Derived Growth FactorIBA 02/2024
1	Alanine Transaminase (SGPT)IBA 02/2024
1	osimertinibIBA 10/2023
1	lazertinibIBA 10/2023
1	Peptides (Polypeptides)IBA 01/2023
1	B7-H1 AntigenIBA 01/2023
1	relatlimabIBA 01/2023
1	EpitopesIBA 01/2023
1	insulin receptor-related receptor (IRR)IBA 01/2023
1	Maytansine (Maitansine)IBA 01/2022
1	varlilumabIBA 01/2022
1	ZirconiumIBA 01/2022
1	Hormones (Hormone)IBA 01/2022
1	Glycoproteins (Glycoprotein)IBA 11/2021
1	CX-2029IBA 01/2021
1	ProdrugsIBA 01/2021
1	IpilimumabIBA 01/2021
1	pepinemabIBA 01/2021
1	Transferrin Receptors (Transferrin Receptor)IBA 01/2021
1	avelumabIBA 01/2021
1	monomethyl auristatin EIBA 01/2021
1	AntibodiesIBA 12/2020
1	Circulating Tumor DNAIBA 11/2019
1	Leucovorin (Folinic Acid)FDA Link 12/2018
1	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 12/2018
1	Fluorouracil (Carac)FDA LinkGeneric 12/2018
1	Celecoxib (Celebrex)FDA Link 12/2018
1	ensartinibIBA 01/2018
1	Anaplastic Lymphoma KinaseIBA 01/2018
1	ruxolitinibIBA 01/2018
1	Janus KinasesIBA 01/2018
1	Interleukin-10 (Interleukin 10)IBA 12/2017
1	VaccinesIBA 12/2017
1	Interleukin-5 (Interleukin 5)IBA 12/2017
1	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 12/2017
1	Proteasome Endopeptidase Complex (Proteasome)IBA 10/2017
1	Proteasome InhibitorsIBA 10/2017
1	vandetanib (ZD6474)IBA 01/2017
1	Etoposide (VP 16)FDA LinkGeneric 01/2017
1	tremelimumabIBA 03/2016
1	apricoxibIBA 01/2015
1	Biomarkers (Surrogate Marker)IBA 01/2015
1	Dinoprostone (PGE2)FDA Link 01/2015
1	resiquimodIBA 04/2014
1	Toll-Like Receptors (Toll-Like Receptor)IBA 04/2014
1	poly ICLCIBA 04/2014
1	Toll-Like Receptor AgonistsIBA 04/2014

Therapy/Procedure

12	Therapeutics 01/2023 - 08/2005
8	Drug Therapy (Chemotherapy) 02/2024 - 10/2012
2	Immunotherapy 01/2021 - 12/2020